FMC Writes Down Its Own Inventory — and Six Quarters of 'One Thing to Fix' With It
A $672 million commercial charge turns a channel problem into a covenant problem, and management quietly retires the growth narrative it spent a year building.
FMC · Earnings Call · 2026-10-30
The quarter that stopped being about the weather
For two years FMC management explained its shortfalls with a short, tidy list: generic pressure in the core portfolio, the Rynaxypyr partner reset, and a slow registration calendar for Isoflex and fluindapyr. The October 15 pre-announcement broke that frame. Q3 revenue came in at $106 million — against $745 million of underlying sales before $639 million of charges — and adjusted EBITDA was negative $559 million. The stock fell 32.4% that morning and is down 45% in the last 90 trading days, 95.6% below its April 2022 peak on a $776 million market cap.
The mechanism is not demand. It is the carrying value of FMC product in someone else's warehouse. As Pierre Brondeau put it, “channel customers are seeking to hold the lowest inventory values we have ever seen” — Pierre Brondeau, Chairman, Chief Executive Officer and President · 2026-10-30. Because the North America business model invoiced at a high gross price with a large rebate settled after the crop season, the number on the customer's balance sheet sat above the net price FMC expected. Add high-priced product sold into Brazil, Argentina, the U.S. and Canada since 2023, and customers had every incentive to stop ordering.
So FMC bought the constraint out of the way. Roughly $500 million resets the gross-to-net pricing structure, non-cash and split about 60/40 between the mechanics and historic channel value; roughly $175 million of credit notes adjusts high priced product already sitting in the channel. The second bucket is the only piece that touches real cash.
To address this issue, we are taking two actions to reduce the value of their FMC channel inventory. These actions are resulting in the third quarter EBITDA impact of $672 million.
This is a genuinely new vocabulary for this company. Across the twelve-quarter keyword history, commercial action, channel inventory, lower rebate and covenant language all appear for the first time at maximum intensity in 2026Q4. There is no precedent quarter where FMC's problem was described as an accounting artifact of its own pricing architecture rather than a competitive or agronomic one.
What management stopped saying
The more telling datapoint is the silence. growth portfolio was FMC's loudest theme as recently as early 2026, carrying the highest momentum in the keyword set; by mid-2026 it was the single sharpest declining theme, and on this call it is a supporting clause, not the thesis. India business — a $250 million headline divestiture with a December 1 close — has also faded from narrative prominence. Even Isoflex, the product Brondeau once said would be "very quickly bigger than Rynaxypyr and Cyazypyr together" in Europe, has slipped from the momentum board.
That matters because it is a reversal of the February framing. Then, the company was insistent that the fix list was short:
“There is one part which I missed... We have one thing to fix. It's the core portfolio.” — Pierre Brondeau, Chairman, Chief Executive Officer and President · 2026-02-05
And in the same call, on cycle timing: “I expect at this point is at the bottom of the cycle for the company.” — Pierre Brondeau, Chairman, Chief Executive Officer and President · 2026-02-05
Nine months later, the "one thing" has a $672 million price tag attached and the bottom has moved. Brondeau is now explicit that cost cannot carry the story: “we are getting to a place where we will not save the performance of the company through future cost savings” — Pierre Brondeau, Chairman, Chief Executive Officer and President · 2026-10-30. The manufacturing footprint work, the plant closures, the 1,000 positions eliminated — all of it is now framed as enabling, not rescuing.
A theme the company also dropped: tariffs. Global cross-section data shows tariff refund as the single hottest market keyword of 2026Q2, with ACCO, AOS, ORLY, BOOM and VFC all citing refunds in the current reporting window. FMC spent a chunk of its July Q&A on exactly this — liquidated versus unliquidated duties, the absence of a recovery process. In October, it is essentially absent. Given a company guiding to negative $150–350 million of free cash flow, a recoverable tariff claim is precisely the kind of swing factor an investor would want quantified.
The covenant is the real quarter
Strip out the noise and the balance sheet is the story. Effective net cash stood at negative $3.8 billion at the last filing, and the company now guides 2026 free cash flow to negative $350 million to negative $150 million. The supporting math is uncomfortable: secured debt to covenant EBITDA of 1.4x against a 3.5x limit, interest coverage of 2.3x against a 2.0x floor, and — the number that matters — total debt to covenant EBITDA at 6.1x against a 6.75x limit that reinstates on December 31.
“while total debt to covenant EBITDA is not formally measured for the third quarter, this metric would have been 6.1x as compared to the 6.75x covenant limit that will be reinstated at December 31, 2026.” — Andrew Sandifer, Executive Vice President and Chief Financial Officer · 2026-10-30
Two things are holding that together. First, the Covenant EBITDA definition explicitly adds back charges like the $672 million commercial action — meaning the reported disaster does not count against the test. Second, the $403 million Tessenderlo Group equity investment, closed September 23, which handed the Belgian group roughly 20% of FMC's common stock and a board seat for Luc Tack. That is a de facto strategic anchor shareholder arriving at the bottom of a drawdown, and it barely got a paragraph.
The 2027 promise, and what the tape says
Management's forward sketch is the bull case: 2027 EBITDA of at least $650 million and as much as $730 million, 2028 at $760–840 million, with the channel transition complete in three quarters, new actives led by fluindapyr adding registrations in six countries, and the diamide partner headwind shrinking. The bridge relies on an 18–19% EBITDA conversion on three buckets Brondeau enumerated live on the call.
Weigh that against a company whose total revenue was $867 million last quarter, down 17% year over year, whose operating margin has collapsed from 20.9% in 2022Q1 to negative territory, and whose 2027 range spans $80 million — a spread Brondeau concedes depends on how fast customers accept the new pricing. Confidence, as he put it, “can only be rebuilt through execution and results” — Pierre Brondeau, Chairman, Chief Executive Officer and President · 2026-10-30.
The honest read is that FMC has done something unusual and arguably correct: it took a large, non-cash charge to destroy the inventory-value overhang that was strangling its order book, and it is paying roughly $175 million in real credit to do it. That is a strategic choice, not an accounting accident. But it arrives at 6.1x leverage, with a covenant stepping down in eight weeks, a 20% shareholder on the register, and a market that has already voted 95% against the equity since 2022. The next two quarters are not about agronomy. They are about whether cash arrives before the covenant does.